Velocity Pharmaceutical Development, LLC

VPD in the news for deal with Baxter Ventures and Mayo Clinic Vitesse formed to identify and advance early stage biologic research in immunology, hematology and oncology http://www.prnewswire.com//baxter-ventures-mayo-clinic-and

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus -- Statistically Significant Data from Phase 2 Study Support Safety and Efficacy of Once Daily Dosing of NK-1 Antagonist, VPD-737 (serlopitant)

Tigercat Pharma, Inc. launches new website http://tigercatpharma.com

Coming Soon! VPD launching new website for Tigercat Pharma, Inc. and VPD-737

VPD Attending 33rd Annual JPM Healthcare Conference, January 12-15, 2015, in San Francisco

Velocity Pharmaceutical Development and Tigercat Pharma, Inc. Presenting at 2nd Annual Dermatology Summit in San Francisco, January 11, 2015

Next week, on October 14th, Velocity Pharmaceutical Development will be presenting at the Sofinnova Japan Partnering Conference in Tokyo. Tigercat Pharma and Spitfire Pharma will be presented at the conference. http://www.sofinnovajapanpartnering.com

http://www.prnewswire.com//velocity-pharmaceutical-develop

Come visit VPD's new website! www.vpd.net

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Regulatory Clearance for Initiating Phase II Study with VPD-737 in Prurigo Nodularis

Next week, June 23-26, Velocity Pharmaceutical Development will be attending the BIO International Convention in San Diego, CA

June 13-17, 2014 Velocity Pharmaceutical Development attending American Diabetes Association - 74th Scientific Sessions in San Francisco, CA